{"groups":[{"description":"Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.","id":"FG000","title":"Lenalidomide Plus Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"154"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"107"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"28"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"18"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Transplant"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"587"}],"type":"STARTED"},{"achievements":[{"comment":"Participants completed the study upon commercial availability of lenalidomide","groupId":"FG000","numSubjects":"256"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"331"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}